• 1. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives N-acylserotonins

Recent Advances in the Study of cis-Moschamine (193224-24-7): A Promising Compound in Chemical Biology and Medicine

In recent years, the compound cis-Moschamine (CAS: 193224-24-7) has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This research briefing aims to summarize the latest findings regarding cis-Moschamine, focusing on its synthesis, biological activities, and pharmacological implications. The compound, a derivative of the Moschamine family, has shown promising results in various preclinical studies, particularly in the areas of anti-inflammatory and neuroprotective effects.

The synthesis of cis-Moschamine has been a focal point of recent research, with several studies optimizing the process to enhance yield and purity. A 2023 study published in the Journal of Medicinal Chemistry detailed a novel catalytic approach that significantly improved the stereoselective synthesis of cis-Moschamine, achieving a yield of over 85%. This advancement is critical for scaling up production for further pharmacological testing and potential clinical applications. The study also highlighted the compound's stability under physiological conditions, which is a key factor for its bioavailability and therapeutic efficacy.

Biological evaluations of cis-Moschamine have revealed its potent anti-inflammatory properties. In vitro studies using macrophage cell lines demonstrated that cis-Moschamine effectively inhibits the production of pro-inflammatory cytokines such as TNF-α and IL-6, with IC50 values in the low micromolar range. These findings were corroborated by in vivo models of acute inflammation, where cis-Moschamine administration led to a significant reduction in edema and inflammatory cell infiltration. Researchers attribute these effects to the compound's ability to modulate the NF-κB signaling pathway, a central regulator of inflammatory responses.

Beyond its anti-inflammatory effects, cis-Moschamine has also shown neuroprotective potential in models of neurodegenerative diseases. A 2024 study in Neuropharmacology reported that cis-Moschamine could mitigate oxidative stress and neuronal apoptosis in a cellular model of Parkinson's disease. The compound's ability to cross the blood-brain barrier, as confirmed by pharmacokinetic studies, further underscores its potential as a therapeutic agent for central nervous system disorders. These findings have sparked interest in exploring cis-Moschamine's utility in other neurodegenerative conditions, such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Despite these promising results, challenges remain in the development of cis-Moschamine as a therapeutic agent. Current research is focused on addressing issues related to its pharmacokinetic profile, including metabolism and elimination rates. Additionally, toxicological studies are underway to ensure the compound's safety for human use. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these findings into clinical trials, with preliminary Phase I studies anticipated within the next two years.

In conclusion, cis-Moschamine (193224-24-7) represents a compelling candidate in the search for novel therapeutic agents with anti-inflammatory and neuroprotective properties. The latest research highlights its potential across multiple disease models, paving the way for further investigation and development. As the scientific community continues to unravel the mechanisms underlying its biological activities, cis-Moschamine may soon emerge as a valuable addition to the pharmacopeia of chemical biology and medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)